Organic Process Research & Development 2006, 10, 28−32
Full Papers
Process Development of (1S,2S,5R,6S)-
Spiro[bicyclo[3.1.0]hexane-2′,5′-dioxo-2,4′-imidazolidine]-6-carboxylic Acid,
(
R)-r-Methylbenzenemethanamine Salt (LSN344309)
,
†
†
†
†
‡
‡
Ossama M. Rasmy,* Radhe K. Vaid, Michael J. Semo, Erik C. Chelius, Roger L. Robey, Charles A. Alt,
‡
†
Gary A. Rhodes, and Jeffery T. Vicenzi
Chemical Product Research and DeVelopment, Eli Lilly and Company, Indianapolis Laboratories, Indiana 46285, and
Tippecanoe Laboratories, Indiana 47905, U.S.A.
Abstract:
hydantoin acid comprising four chemical steps with three
isolated intermediates is shown in Scheme 1.
Process development and a pilot-plant process for the synthesis
of 4 and its resolution to obtain (1S,2S,5R,6S)-spiro[bicyclo-
Evaluation of the processes before scale up revealed some
undesirable features such as: (a) emission of the air
pollutants dimethyl sulfide and ethyl bromoacetate during
the filtration in step 1 and (b) irreproducibility of the yield
and purity of 5 when acetone/water was used as a crystal-
lization medium.
Therefore, our development efforts were focused on
addressing these issues and improving processing.
Herein, we describe the results of these efforts.
[3.1.0]hexane-2′,5′-dioxo-2,4′-imidazolidine]-6-carboxylic acid,
(R)-r-methylbenzenemethanamine salt (5) are described. Start-
ing from the inexpensive raw 2-cyclopenten-1-one and sulfur
ylide 1 the racemic bicyclo keto ester 2 was synthesized.
Reaction of 2 with potassium cyanide and ammonium carbonate
under B u1 cherer-Berg’s reaction conditions affords racemic 3
in 80% yield. Hydrolysis of 3 followed by the resolution with
(R)-(+)-r-methylbenzylamine gave 4 in excellent yield and
purity under optimized conditions. The improvement of the
original discovery process to accommodate safety and environ-
mental requirements for scale-up in manufacturing facilities is
also discussed.
Results and Discussion
The bicyclic ketone 2 is readily synthesized by the
reaction of 2-cyclopentenone with either a diazoester or with
6,7
a sulfur ylide. Although use of a diazoester avoids the odor
and emission problems associated with the use of a sulfur
ylide and particularly the sulfur ylide generated from 1, the
safety issues associated with handling diazoesters preclude
their use in a commercial manufacturing setting. Thus,
process development focused on the use of a sulfur ylide.
In the initial discovery synthesis, the sulfonium salt 1
resulting from reaction of dimethyl sulfide and ethylbro-
moacetate was isolated as a crystalline solid. Both the
isolation of 1 and its use in step two pose significant odor
and volatile emission control problems. One attractive
solution to this problem is the use of a nonvolatile polymeric
sulfide in the formation of the sulfonium salt and corre-
sponding ylide in steps 1 and 2. However, all our attempts
to synthesize 2 using a polymeric sulfide in reaction with
ethylbromoacetate to prepare the desired sulfonium salt and
corresponding ylide were unsuccessful. Thus, efforts focused
on odor and emission minimization by the in situ generation
of 1. Ideally, by combining steps 1 and 2, all processing
involving the use or generation of dimethyl sulfide could be
conducted in a closed vessel. The dimethyl sulfide would
Introduction
LY544344 hydrochloride 6 is a new chemical entity under
investigation by Eli Lilly & Company as a potential treatment
of neurological or psychiatric disorders related to the
1
mammalian central nervous system (CNS). Compound 5 is
a key intermediate in the synthesis of 6. The original route
involved the synthesis of racemic hydantoin acid 4 followed
by resolution using (R)-(+)-(R)-methylbenzyylamine in
acetone/water (Scheme 1).2 The synthesis of the racemic
-5
*
To whom correspondence should be addressed. E-mail: rasmy_osama_m@
lilly.com.
†
Chemical Product Research and Development, Eli Lilly and Company.
Tippecanoe Laboratories.
‡
(
1) Bueno Melendo, A. B.; Coffey, D. S.; Dantzing A. H.; De Dios, A.;
Dominguez-Fernandez, C.; Merin, M.; Hillgren, K. M.; Martin, J. A.; Martin-
Cabrejas, L. M.; Martinez-Grau, M. A.; Massey, S. M.; Moher, E. D.; Monn,
J. A.; Montero Salgado, C.; Pedersen, S. W.; Pedregal-Tercero, C.; Sweetana,
S. A.; Valli, M. J. WO 02/055481, 2002; Chem Abstr. 2002, 137, 94004.
2) Helton, D. R.; Kallman, M. J.; Monn, J. A.; Schoepp, D. D.; Tizzano, J. P.
U.S. Patent 5,661,184, 1997; Chem. Abstr. 1997, 127, 205300.
3) Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.;
Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey,
K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. J.
Med. Chem. 1997, 40, 528-537.
(
(
(5) Schoepp, D. D.; Johnson, B. G.; Wright, R. A.; Salhoff, C. R.; Mayne, N.
G.; Wu, S.; Cockerham, S. L.; Burnett, J. P.; Belegaje, R.; et al.
Neuropharmacology 1997, 36, 1-11.
(6) Payne, G. B. J. Org. Chem. 1967, 32, 3351-3355.
(7) La Porta, E.; Piarulli, U.; Cardullo, F.; Paio, A.; Provera, S.; Seneci, P.;
Gennari, C. Tetrahedron Lett. 2002, 43, 761-766.
(
4) Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.;
Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson,
B. G.; Andis, S. L.; Kingsston, A.; Tomlinson, R.; Lewis, R.; Griffey, K.
R.; Tizzano, J. P.; Schoepp, D. D. J. Med. Chem. 1999, 42, 1027-1040.
2
8
•
Vol. 10, No. 1, 2006 / Organic Process Research & Development
10.1021/op049829e CCC: $33.50 © 2006 American Chemical Society
Published on Web 12/01/2005